RBC Capital Sticks to Their Hold Rating for Sangamo Biosciences (SGMO)

In a report released yesterday, Luca Issi from RBC Capital maintained a Hold rating on Sangamo Biosciences (SGMO – Research Report), with a price target of $2.00. The company’s shares closed yesterday at $1.01.

Light Up your Portfolio with Spark:

• Easily identify stocks' risks and opportunities.
• Discover stocks' market position with detailed competitor analyses.

Issi covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Moderna, and Arrowhead Pharmaceuticals. According to TipRanks, Issi has an average return of -20.2% and a 22.14% success rate on recommended stocks.

In addition to RBC Capital, Sangamo Biosciences also received a Hold from Wells Fargo’s Yanan Zhu in a report issued today. However, on the same day, Barclays maintained a Buy rating on Sangamo Biosciences (NASDAQ: SGMO).

SGMO market cap is currently $204.7M and has a P/E ratio of -1.36.